| P50 | author | Sean E Kennedy | Q79294806 |
| P2093 | author name string | Nigel Mackman | |
| | Jonathan H Erlich | |
| | Kate Wilson | |
| | John A Charlesworth | |
| | Darren R Davis | |
| | Melissa J Sam | |
| P2860 | cites work | Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling | Q33895464 |
| | Tissue factor deficiency causes cardiac fibrosis and left ventricular dysfunction | Q34385821 |
| | Matrix metalloproteinases: regulation and dysregulation in the failing heart | Q34574541 |
| | Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. | Q35083397 |
| | Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure | Q35284582 |
| | Matrix metalloproteinases A review of their structure and role in acute coronary syndrome | Q35557333 |
| | Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor | Q35559979 |
| | Gender modulates cardiac phenotype development in genetically modified mice | Q35846955 |
| | Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window | Q36344710 |
| | Low levels of tissue factor are compatible with development and hemostasis in mice. | Q37377780 |
| | Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice | Q38584976 |
| | Regulation of vascular endothelial growth factor (VEGF) production and angiogenesis by tissue Factor (TF) in SGC-7901 gastric cancer cells | Q40431822 |
| | A quantitative real-time PCR method for tissue factor mRNA. | Q40589336 |
| | Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. | Q40859813 |
| | Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. | Q40880354 |
| | Neonatal estrogen stimulates proliferation of periductal fibroblasts and alters the extracellular matrix composition in the rat prostate | Q42466503 |
| | CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis | Q42494057 |
| | Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis | Q43939993 |
| | Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor | Q44820276 |
| | Role of tissue factor in embryonic blood vessel development. | Q45878003 |
| | Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system | Q45889584 |
| | Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy | Q46420655 |
| | Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. | Q53631087 |
| | Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. | Q54036709 |
| | The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities | Q59261168 |
| | A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure | Q59599298 |
| | Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure | Q62383757 |
| | Thrombin increases proliferation and decreases fibrinolytic activity of kidney glomerular epithelial cells | Q67912533 |
| | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride | Q72861447 |
| | Stromelysin (MMP-3) synthesis is up-regulated in estrogen-deficient mouse osteoblasts in vivo and in vitro | Q73204923 |
| | Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat | Q73693685 |
| | Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells | Q73832884 |
| | Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro | Q74214063 |
| | Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation | Q74292354 |
| | Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1 | Q77426354 |
| | Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice | Q80422543 |
| | A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice | Q81144269 |
| | The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat | Q81208214 |
| P433 | issue | 3 | |
| P304 | page(s) | 559-571 | |
| P577 | publication date | 2007-01-17 | |
| P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
| P1476 | title | The development of cardiac fibrosis in low tissue factor mice is gender-dependent and is associated with differential regulation of urokinase plasminogen activator | |
| P478 | volume | 42 | |